Skip to search formSkip to main contentSkip to account menu

KE 298

Known as: KE-298 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

esonarimod

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
The new antirheumatic drug KE-298 suppresses monocyte chemoattractant protein (MCP)-1 and RANTES production in rats with adjuvant-induced arthritis and in IL-1β-stimulated synoviocytes of patients…
Abstract. We analyzed the effects of the new antirheumatic drug KE-298 on monocyte chemoattractant protein (MCP)-1 and regulated… 
2001
2001
KE-298 and its active metabolite KE-758 suppress nitric oxide production by murine macrophage cells and peritoneal cells from rats with adjuvant induced arthritis.
OBJECTIVE To analyze the effects of KE-298 and KE-758 on lipopolysaccharide (LPS) induced nitric oxide (NO) production by the… 
2001
2001
New disease-modifying antirheumatic drug 2 acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid (KE-298) selectively augments activation-induced T cell death.
We examined in this study whether the newly developed disease-modifying antirheumatic drug (DMARD) 2-acetylthiomethyl-4-(4… 
1998
1998
Suppressive effects of the new antirheumatic drug KE-298 on TNF alpha-induced production of matrix metalloproteinases but not of tissue inhibitor-1 of metalloproteinases in human rheumatoid…
KE-298 is a novel antirheumatic drug which suppresses various animal models of arthritis by inhibiting the production of… 
1997
1997
Stereoselective disposition and chiral inversion of KE-298, a new antirheumatic drug, in rats.
The present study was an attempt to elucidate the relationship between stereoselective pharmacokinetics and protein binding of KE… 
1996
1996
Pharmacological profile of KE-758, the main metabolite of the antirheumatic agent KE-298.
KE-298(2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid) is a newly developed antirheumatic drug which suppresses the… 
1996
1996
Identification of metabolites of KE-298, a new antirheumatic drug, and its physiological properties in rats.
To characterize the pharmacokinetic properties of a new antirheumatic drug, KE-298, the metabolic fate of [14C]labeled KE-298 in… 
1996
1996
Stereoselective pharmacokinetics of [14C]-labeled KE-298, a new anti-rheumatic drug, in rats.
The stereoselective pharmacokinetics of two enantiomers of [14C]-labeled KE-298 [2-acetylthiomethyl-4-(4-methylphenyl)-4… 
1996
1996
Preparation and antirheumatic activity of optically active 2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid (KE-298).
2-Acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanonic acid (KE-298) is an antirheumatic agent. To elucidate the effects of… 
1996
1996
Effect of KE-298 on experimental arthritis in mice.
KE-298 is a new immunomodulatory agent with a chemical structure similar to that of D-penicillamine. We compared the effects of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)